Cardurion Pharmaceuticals is going shopping for more cardio drug candidates.
The Burlington, MA-based biotech, which launched in 2017 with a
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Tecelra is genetically engineered to target melanoma-associated antigen A4 (MAGE-A4). Image: Shutterstock/Christoph Burgstedt Oxford-based cell therapy company Adaptimmune Therapeutics has received accelerated approval from the
Share this article The advancement aims to provide a simplified and comprehensive solution for the manufacturing requirements of customers. Credit: Dmitry Kalinovsky / Shutterstock.com. Contract
A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer